Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
Kazia Therapeutics Limited (KZIA) entered into an underwriting agreement for a tranched underwritten public offering of ADSs, pre-funded warrants and Series A and B warrants at a combined public offering price of $15.50 per ADS and accompanying warrants, for expected gross proceeds of approximately $40 million before expenses.
The Series A Warrants cover up to 2,243,478 ADSs at $17.825 per ADS and the Series B Warrants cover up to 2,064,000 ADSs at $19.375 per ADS, which, if fully exercised, could provide about $80 million in additional gross proceeds. Pre-funded warrants have a de minimis $0.0001 exercise price and do not expire until fully exercised.
Warrants become non-exercisable 30 days after specified paxalisib Phase 1b and HR+/HER2- breast cancer progression-free survival milestones or five years from issuance, whichever is earlier, and include beneficial ownership limitations. Net proceeds are intended primarily to fund clinical development of paxalisib and for working capital and general corporate purposes. Company executives and directors agreed to a 60-day lock-up on additional equity sales.
Kazia Therapeutics Limited (KZIA) is conducting an underwritten shelf takedown offering of 2,276,800 ADSs (each ADS representing 500 ordinary shares) at $15.50 per ADS and accompanying warrants, plus Pre-Funded Warrants for 303,200 ADSs at $15.4999 each and accompanying warrants, for gross proceeds of about $40.0 million and estimated net proceeds of about $37.2 million.
Each ADS or Pre-Funded Warrant is sold together with Series A Warrants to purchase up to 2,243,478 ADSs at $17.825 and Series B Warrants to purchase up to 2,064,000 ADSs at $19.375. The warrants are immediately exercisable, have milestone-based/5‑year expirations, and will not be listed. If all Pre-Funded, Series A and Series B Warrants are exercised, ordinary shares outstanding would rise from 7.77 billion post-closing to 9.93 billion on a fully as‑adjusted basis.
Kazia expects to use the net proceeds primarily to advance its lead oncology drug paxalisib in multiple indications, including ongoing Phase 1b triple‑negative breast cancer (TNBC) work and new trials in HR+/HER2‑ breast cancer, colorectal cancer, and early-stage high‑risk TNBC, and for working capital. The company reports promising early TNBC data, including an 83% objective response rate in six evaluable patients, but emphasizes these results are preliminary. Auditors have included a going‑concern explanatory paragraph in prior financials.
Kazia Therapeutics Limited (KZIA) has reduced the capacity of its at-the-market issuance program for American Depositary Shares. A prospectus supplement filed on August 28, 2026 amends the existing Sales Agreement with Leerink Partners LLC, lowering the maximum aggregate offering price of ADSs that may be offered, issued and sold under the program from $100,000,000 to $80,000,000. This supplement relates to the company’s effective shelf registration statement on Form F-3 (File No. 333-294392).
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement updating its at-the-market offering program of American Depositary Shares (ADSs) under its Form F-3 shelf. The company reduced the maximum aggregate offering price of ADSs that may be offered under its Sales Agreement with Leerink Partners LLC from $100,000,000 to $80,000,000, including ADSs previously sold. As of this supplement, Kazia has sold 510,000 ADSs for approximately $5,106,516 under the agreement. Each ADS represents 500 ordinary shares, and the ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a closing price of $16.90 per ADS on August 27, 2026.
Kazia Therapeutics Limited (KZIA) is conducting an underwritten public offering of American Depositary Shares (ADSs), each representing 500 ordinary shares, together with Series A and Series B warrants, and is also offering pre-funded warrants in lieu of ADSs to certain investors. Each ADS or pre-funded warrant is sold as a fixed package with one Series A and one Series B warrant; the warrants are immediately exercisable but will not be listed on an exchange, while the ADSs trade on Nasdaq under the symbol KZIA, which last closed at $14.60 per ADS on August 26, 2026.
As of December 31, 2025, Kazia had 5,020,465,734 ordinary shares outstanding, cash and cash equivalents of $69.46 million, and total equity of $46.47 million. Historical net tangible book value was $0.01 per ordinary share, or about $2.68 per ADS, indicating investors in this offering may experience dilution. The company qualifies as a foreign private issuer and reports under IFRS, with its books in Australian dollars.
Net proceeds are intended primarily to advance lead oncology candidate paxalisib, including an ongoing Phase 1b trial in advanced triple‑negative breast cancer (TNBC) with pembrolizumab and chemotherapy, and planned expansions into HR+/HER2‑ breast cancer, colorectal cancer and early-stage high-risk TNBC. In the TNBC program, six of six evaluable patients on paxalisib-based regimens showed clinical benefit, with an 83% objective response rate (one complete and four partial responses, one stable disease) and no paxalisib‑related serious adverse events reported, though the dataset remains small and early.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement relating to its Form F-1 registration, covering 10,700,211 American Depositary Shares (ADSs) representing 5,350,105,500 ordinary shares. The supplement attaches an August 27, 2026 Form 6-K with new clinical and corporate information.
Kazia reports early data for its lead drug paxalisib in Stage IV triple-negative breast cancer: all six evaluable patients achieved clinical benefit, with an 83% objective response rate (one complete and four partial responses) and one durable complete metabolic response ongoing since November 2025. Median reductions were 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells, with no paxalisib-related serious adverse events.
The investor presentation describes a broader oncology pipeline, including paxalisib in multiple solid tumors and preclinical PD-L1 degrader and SETDB1 programs. Kazia reports approximately US$46 million in cash and equivalents as of December 31, 2025, no debt, and about 14.1 million fully diluted ADSs, with funding expected to support planned operations into 2029, excluding additional or expanded trials.
Kazia Therapeutics Limited (KZIA) has filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs) representing 116,478,000 ordinary shares, updating its existing Form F-1 prospectus with new August 27, 2026 disclosures. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $14.60 per ADS on August 26, 2026.
The update incorporates a Form 6-K that includes new clinical data for lead asset paxalisib in Stage IV triple-negative breast cancer (TNBC). In six evaluable patients, the company reports a 100% clinical benefit rate, with 5 of 6 patients (83%) achieving objective responses (one complete, four partial) and one patient achieving stable disease, alongside no paxalisib-related serious adverse events. Translational analyses showed median reductions of about 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells, while total CD8+ T-cell counts remained stable.
Kazia states it had approximately $46 million in cash and cash equivalents as of December 31, 2025, with no outstanding debt and about 14.1 million fully diluted ADSs outstanding, and that this cash is expected to fund planned operations into 2029, excluding additional or expanded trials. The supplement also furnishes an investor presentation describing paxalisib’s broader development in glioblastoma, other breast cancer subtypes and colorectal cancer, and preclinical programs NDL2 (PD-L1 degrader) and MSETC (SETDB1 inhibitor).
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 266,666 American Depositary Shares (ADSs), each ADS representing ordinary shares, and attached an August 27, 2026 Form 6-K with updated clinical and corporate information. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $14.60 per ADS on August 26, 2026.
The company reported early data for its lead drug paxalisib in six evaluable patients with Stage IV triple-negative breast cancer. All six achieved clinical benefit, with an objective response rate of 83% (one complete and four partial responses) and one remaining patient with stable disease. Across these patients, median reductions were 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells, while no treatment-related serious adverse events were observed. Kazia plans to complete enrollment in its ongoing Phase 1b TNBC study by July 2027 and to expand paxalisib development into HR+/HER2− breast cancer and pMMR colorectal cancer.
The investor presentation indicates cash and cash equivalents of about $46 million as of December 31, 2025, no outstanding debt, and approximately 14.1 million fully diluted ADSs outstanding. The company expects this cash to fund planned operations into 2029, excluding additional or expanded trials, and outlines intended use of offering proceeds to advance paxalisib trials and its preclinical PD‑L1 degrader (NDL2) and SETDB1 inhibitor (MSETC) programs.
KAZIA THERAPEUTICS LTD (KZIA) filed a prospectus supplement for an existing Form F-1 offering covering 95,110 American Depositary Shares (ADSs), each representing ordinary shares, and updating investors with new clinical and corporate information. The ADSs trade on Nasdaq under symbol KZIA; the last reported price was $14.60 per ADS on August 26, 2026.
The attached Form 6-K highlights early Phase 1b data for lead asset paxalisib in six evaluable patients with Stage IV triple-negative breast cancer, showing a 100% clinical benefit rate, including 1 complete and 4 partial responses, plus reductions in metastasis-associated circulating tumor cell clusters and terminally exhausted CD8+ T cells, with no paxalisib-related serious adverse events reported. Kazia also outlines broader development plans for paxalisib across glioblastoma, advanced breast cancer and pMMR colorectal cancer, and preclinical programs NDL2 and MSETC, alongside a capital position of approximately US$46 million in cash and cash equivalents and about 14.1 million fully diluted ADSs outstanding.
KAZIA THERAPEUTICS LTD (KZIA) reports very early but striking Phase 1b data for its lead drug paxalisib in Stage IV triple-negative breast cancer. In six evaluable patients, the company reports a 100% clinical benefit rate, with one complete response, four partial responses and one case of stable disease, for an 83% objective response rate. Median reductions reached 83% in circulating tumor cell clusters by 6–7 weeks and 51% in terminally exhausted CD8+ T cells within about three weeks, while total CD8 counts were maintained. No paxalisib-related serious adverse events were observed in these patients, and the company highlights a durable complete metabolic response in one patient ongoing since November 2025. Kazia positions paxalisib as a dual PI3K/mTOR inhibitor with epigenetic and immunomodulatory activity, with ongoing and planned studies in TNBC, HR+/HER2- breast cancer, pMMR colorectal cancer, glioblastoma and pediatric brain tumors. The investor presentation also notes approximately US$46 million in cash and equivalents as of December 31, 2025, no debt, roughly 14.1 million fully diluted ADS outstanding, and an intention to conduct an equity offering under an effective F-3 shelf.